Ionis Pharmaceuticals, Inc.
IONS
Classificação em ações
#2583
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Preço da ação
$44.35
Última sincronização: 2026-10-19
Valor de mercado
$7.37B
Variação (1 dia)
3.28%
Variação (1 ano)
-39.70%
País
US
Negociar Ionis Pharmaceuticals, Inc. (IONS)
Categoria
Healthcare
Rácio P/S de Ionis Pharmaceuticals, Inc. (IONS)
Rácio P/S em October 2026 TTM: 8.12
De acordo com os relatórios financeiros mais recentes e o preço das ações da Ionis Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 8.12. No final de 2023, o rácio P/S era 9.18.
Histórico do rácio P/S da Ionis Pharmaceuticals, Inc. de 2000 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 8.12 | 9.60% |
| 2024 | 7.41 | -19.29% |
| 2023 | 9.18 | 0.63% |
| 2022 | 9.13 | 72.28% |
| 2021 | 5.30 | -51.07% |
| 2020 | 10.83 | 43.78% |
| 2019 | 7.53 | -36.87% |
| 2018 | 11.93 | -2.92% |
| 2017 | 12.29 | -26.29% |
| 2016 | 16.67 | -35.99% |
| 2015 | 26.04 | -23.25% |
| 2014 | 33.93 | 13.51% |
| 2013 | 29.89 | 190.50% |
| 2012 | 10.29 | 41.89% |
| 2011 | 7.25 | -21.60% |
| 2010 | 9.25 | 3.19% |
| 2009 | 8.96 | -28.35% |
| 2008 | 12.51 | -33.96% |
| 2007 | 18.94 | -43.76% |
| 2006 | 33.68 | 310.28% |
| 2005 | 8.21 | 4.71% |
| 2004 | 7.84 | 8.72% |
| 2003 | 7.21 | 61.05% |
| 2002 | 4.48 | -75.63% |
| 2001 | 18.37 | 74.01% |
| 2000 | 10.56 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | 23.41% |
US
|
|
| 40.55 | 399.31% |
US
|
|
| 3.96 | -51.23% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 24.93% |
NL
|
